Sion Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to improve CFTR protein function in cystic fibrosis patients, focusing on a previously undruggable region of the protein not targeted by existing therapies. The company's pipeline includes NBD1 stabilizers designed to restore normal CFTR activity, either as add-on therapy to current standard-of-care treatments or in combination with complementary modulators, addressing the significant unmet medical need among the majority of cystic fibrosis patients who lack adequate CFTR function despite existing medications. Sion generates value through milestone payments and royalty arrangements with strategic partners including Sanofi and AbbVie, while targeting a global patient population of approximately 100,000 concentrated in specialized treatment centers that support efficient commercialization.